Replies to post #405443 on Anavex Life Sciences Corp (AVXL)

[Anshu2]

IMO, market is smart. They know that P2b/P3 has no chance of supporting approval. The stock is still around $10. I think thats a fair price or even lower-than-fair price, even with a P2b/P3 semi-failure.

BTW, I should correct myself --- I don't think P2b/P3 has failed altogether.... I'd say it just has no chance to be pivotal (Meeting delta-Cog and CDR endpoints is very commendable, and perhaps, the reason that the stock is still worth buying).